Methamphetamine-associated cardiomyopathy

Clinical Cardiology

Volumn 36, Issue 12, 2013, Pages 737-742

  Won, Sekon ^a   Hong, Robert A ^a   Shohet, Ralph V ^a   Seto, Todd B ^a   Parikh, Nisha I ^a  

^a UNIVERSITY OF HAWAII   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; ARIPIPRAZOLE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIOVASCULAR AGENT; CATECHOLAMINE; DEXAMPHETAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOPAMINE; EPHEDRINE; ILLICIT DRUG; METHAMPHETAMINE; METHAMPHETAMINE ANTIBODY; MONOCLONAL ANTIBODY; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ADRENERGIC STIMULATION; ALCOHOLISM; AORTA DISSECTION; ASTHMA; ATHEROSCLEROSIS; ATTENTION DEFICIT DISORDER; CARDIOMYOPATHY; CARDIOVASCULAR MAGNETIC RESONANCE; CAREGIVER; CASE REPORT; CATECHOLAMINE RELEASE; CHEMICAL STRUCTURE; CLINICAL STUDY; CONGESTIVE CARDIOMYOPATHY; CORONARY ARTERY SPASM; DEPRESSION; DISEASE ASSOCIATION; FATIGUE; HAY FEVER; HUMAN; HYPERTENSION; INCIDENCE; METHAMPHETAMINE ASSOCIATED CARDIOMYOPATHY; METHAMPHETAMINE DEPENDENCE; NARCOLEPSY; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHYSICIAN; PREVALENCE; PROGNOSIS; REVIEW; RISK FACTOR; SHOCK; SUDDEN CARDIAC DEATH; TACHYCARDIA; VASOSPASM;

AMPHETAMINE-RELATED DISORDERS; ANIMALS; CARDIOMYOPATHIES; CENTRAL NERVOUS SYSTEM STIMULANTS; HUMANS; INCIDENCE; METHAMPHETAMINE; PREVALENCE; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS;

EID: 84890123600     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22195     Document Type: Review

References (45)

1. United Nations Office on Drugs and Crime. World Drug Report 2010. http://www.unodc.org/documents/wdr/WDR-2010/World-Drug-Report-2010-lo-res.pdf.
2. US Department of Health and Human Services, Healthcare Cost and Utilization Project, Agency for Healthcare Research and Quality. Statistics for US community hospital stays, principal diagnosis based on CCS (Clinical Classifications Software), 2010. http://hcupnet.ahrq.gov/HCUPnet.jsp?Id= C4D88AA0629A6D0E&Form=DispTab&JS=Y&Action=%3E%3ENext%3E%3E&- InDispTab=Yes&-Results=Print&SortOpt=.
3. Diercks DB, Fonarow GC, Kirk JD, et al; ADHERE Scientific Advisory Committee and Investigators. Illicit stimulant use in a United States heart failure population presenting to the emergency department (from the Acute Decompensated Heart Failure National Registry Emergency Module). Am J Cardiol. 2008; 102: 1216-1219.
4. Schep LJ, Slaughter RJ, Beasley DM,. The clinical toxicology of metamfetamine. Clin Toxicol (Phila). 2010; 48: 675-694.
5. Cho AK,. Ice: a new dosage form of an old drug. Science. 1990; 249: 631-634.
6. Gal J., Amphetamines in nasal inhalers. J Toxicol Clin Toxicol. 1982; 19: 517-518.
7. Drug and Alcohol Services Administration System, Substance Abuse and Mental Health Services Administration. The DASIS Report: Smoked Methamphetamine/Amphetamines, 1992-2002. http://www.samhsa.gov/data/2k4/ MethSmoked/MethSmoked.htm. Published January 7, 2005.
8. Cook CE, Jeffcoat AR, Hill JM, et al. Pharmacokinetics of methamphetamine self-administered to human subjects by smoking S-(+)-methamphetamine hydrochloride. Drug Metab Dispos. 1993; 21: 717-723.
9. Kim I, Oyler JM, Moolchan ET, et al. Urinary pharmacokinetics of methamphetamine and its metabolite, amphetamine following controlled oral administration to humans. Ther Drug Monit. 2004; 26: 664-672.
10. Valentine JL, Middleton R,. GC-MS identification of sympathomimetic amine drugs in urine: rapid methodology applicable for emergency clinical toxicology. J Anal Toxicol. 2000; 24: 211-222.
11. Fleckenstein AE, Volz TJ, Riddle EL, et al. New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol. 2007; 47: 681-698.
12. Busto U, Bendayan R, Sellers EM,. Clinical pharmacokinetics of non-opiate abused drugs. Clin Pharmacokinet. 1989; 16: 1-26.
13. Katzung BG, ed. Basic and Clinical Pharmacology. 8th ed. New York, NY: Lange Medical Books/McGraw-Hill; 2001.
14. Suwaki H, Fukui S, Konuma K,. Methamphetamine abuse in Japan: its 45-year history and the current situation. In:, Klee H, ed. Amphetamine Misuse: International Perspectives on Current Trends. Amsterdam: Harwood Academic Publishers; 1997.
15. Bruneton J., Toxic Plants Dangerous to Humans and Animals. Paris: Intercept-Lavoisier; 1999.
16. Grinspoon L, Hedblom P,. The Speed Culture: Amphetamine Use and Abuse in America. Cambridge, MA: Harvard University Press; 1975.
17. Anglin MD, Burke C, Perrochet B, et al. History of the methamphetamine problem. J Psychoactive Drugs. 2000; 32: 137-141.
18. US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration. Results from the 2011 National Survey on Drug Use and Health: Summary of National Findings. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2012. http://www.samhsa.gov/data/NSDUH/ 2k11Results/NSDUHresults2011.htm#2.3.
19. Drug and Alcohol Services Administration System, Substance Abuse and Mental Health Services Administration. The DASIS Report, Chapter 2: Trends in Substance Abuse Treatment Admissions, 1994-2004. http://wwwdasis.samhsa.gov/ teds04/TEDSAd2k4Chp2.htm.
20. Hart CL, Gunderson EW, Perez A, et al. Acute physiological and behavioral effects of intranasal methamphetamine in humans. Neuropsychopharmacology. 2008; 33: 1847-1855.
21. Gericke O., Suicide by ingestion of amphetamine sulfate. JAMA. 1945; 128: 1098-1099.
22. Kalant H, Kalant OJ,. Death in amphetamine users: causes and rates. Can Med Assoc J. 1975; 112: 299-304.
23. Rajs J, Falconer B,. Cardiac lesions in intravenous drug addicts. Forensic Sci Int. 1979; 13: 193-209.
24. Jacobs LJ,. Reversible dilated cardiomyopathy induced by methamphetamine. Clin Cardiol. 1989; 12: 725-727.
25. Wijetunga M, Seto T, Lindsay J, et al. Crystal methamphetamine-associated cardiomyopathy: tip of the iceberg? J Toxicol Clin Toxicol. 2003; 41: 981-986.
26. Yeo KK, Wijetunga M, Ito H, et al. The association of methamphetamine use and cardiomyopathy in young patients. Am J Med. 2007; 120: 165-171.
27. Ito H, Yeo KK, Wijetunga M, et al. A comparison of echocardiographic findings in young adults with cardiomyopathy: with and without a history of methamphetamine abuse. Clin Cardiol. 2009; 32: E18-E22.
28. Lopez JE, Yeo K, Caputo G, et al. Recovery of methamphetamine associated cardiomyopathy predicted by late gadolinium enhanced cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2009; 11: 46.
29. Kaye S, McKetin R; National Drug and Alcohol Research Centre (Australia). Cardiotoxicity Associated With Methamphetamine Use and Signs of Cardiovascular Pathology Among Methamphetamine Users. Sydney: NDARC; 2005.
30. Lord KC, Shenouda SK, McIlwain E, et al. Oxidative stress contributes to methamphetamine-induced left ventricular dysfunction. Cardiovasc Res. 2010; 87: 111-118.
31. Chen JP,. Methamphetamine-associated acute myocardial infarction and cardiogenic shock with normal coronary arteries: refractory global coronary microvascular spasm. J Invasive Cardiol. 2007; 19: E89-E92.
32. Hong R, Matsuyama E, Nur K,. Cardiomyopathy associated with the smoking of crystal methamphetamine. JAMA. 1991; 265: 1152-1154.
33. Kaiho M, Ishiyama I,. Morphological study of acute myocardial lesions experimentally induced by methamphetamine. Nihon Hoigaku Zasshi. 1989; 43: 460-468.
34. Srikanth S, Barua R, Ambrose J,. Methamphetamine-associated acute left ventricular dysfunction: a variant of stress-induced cardiomyopathy. Cardiology. 2008; 109: 188-192.
35. Elian D, Harpaz D, Sucher E, et al. Reversible catecholamine-induced cardiomyopathy presenting as acute pulmonary edema in a patient with pheochromocytoma. Cardiology. 1993; 83: 118-120.
36. Abraham J, Mudd JO, Kapur NK, et al. Stress cardiomyopathy after intravenous administration of catecholamines and beta-receptor agonists. J Am Coll Cardiol. 2009; 53: 1320-1325.
37. Samuels MA,. The brain-heart connection. Circulation. 2007; 116: 77-84.
38. Mendelson J, Jones RT, Upton R, et al. Methamphetamine and ethanol interactions in humans. Clin Pharmacol Ther. 1995; 57: 559-568.
39. Mooney ME, Herin DV, Schmitz JM, et al. Effects of oral methamphetamine on cocaine use: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend. 2009; 101: 34-41.
40. 31phosphorus magnetic resonance spectroscopy. Circulation. 2013; 127: AP014.
41. Fleury G, De La Garza R, 2nd, Mahoney JJ 3rd, et al. Predictors of cardiovascular response to methamphetamine administration in methamphetamine-dependent individuals. Am J Addict. 2008; 17: 103-110.
42. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction-executive summary. J Am Coll Cardiol. 2007; 50: 652-726.
43. Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009; 119: e391-e479.
44. Gentry WB, Laurenzana EM, Williams DK, et al. Safety and efficiency of an anti-(+)-methamphetamine monoclonal antibody in the protection against cardiovascular and central nervous system effects of (+)-methamphetamine in rats. Int Immunopharmacol. 2006; 6: 968-977.
45. Sevak RJ, Vansickel AR, Stoops WW, et al. Discriminative-stimulus, subject-rated, and physiological effects of methamphetamine in humans pretreated with aripiprazole. J Clin Psychopharmacol. 2011; 31: 470-480.